Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL
Authors:
- Marco PicardiMarco Picardi
- Roberta Della PepaRPRoberta Della Pepa
- Claudia GiordanoCGClaudia Giordano
- Irene ZacheoIZIrene Zacheo
- Novella PuglieseNPNovella Pugliese
- Chiara MortaruoloCMChiara Mortaruolo
- Fabio TrastulliFTFabio Trastulli
- Antonio GiordanoAGAntonio Giordano
- Mariano LucignanoMLMariano Lucignano
- Maria Di PernaMPMaria Di Perna
- Marta RaimondoMRMarta Raimondo
- Claudia SalvatoreCSClaudia Salvatore
- 31 January 2019
- journal article
- letter
- Published by American Society of Hematology in Blood
- Vol. 133 (5) , 498-501
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivationOncotarget, 2016
- American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug TherapyGastroenterology, 2015
- Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP ChemotherapyJAMA, 2014
- The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary centerEuropean Journal of Internal Medicine, 2014
- Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study GroupEuropean Journal of Cancer, 2013
- Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological diseaseLiver International, 2013
- Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapyJournal of Viral Hepatitis, 2010
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993